· Health Care Equipment · S&P SmallCap 600
LMAT LEMAITRE VASCULAR $1.8B
No. The only AI sentence is a European law.
1 of 15
Reach, Weight, and Proof.
Last updated score 31 AugLast review 31 AugLast earnings call —Next earnings call expected 4 Nov
What they are doing
LeMaitre's 10-K does not describe an AI product or an AI use in the vascular business. The phrase appears once, as the EU Artificial Intelligence Act, a compliance cost with a rolling start in 2025.
Why the score
- Reach 0 not 1: complying with a law is not a function on the chain.
- Weight 0 not 1: no experiment.
- Proof 1 not 0: the Act is named.
- Proof 1 not 2: not tied to an operating use.
What would move it next quarter: A named intelligence layer in a vascular product. Another compliance paragraph will not move this.
Open these first
Evidence
In 2023, Europe finalized the first comprehensive legal framework for governance of the use of artificial intelligence, the EU Artificial Intelligence Act, with a rolling effective date that commenced in 2025. Compliance has caused and will cause additional costs.